Enanta Pharmaceuticals (ENTA) Competitors $9.34 +0.03 (+0.32%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ENTA vs. GNFT, RLAY, ERAS, CRGX, AVXL, CGEM, TECX, TRDA, ORIC, and ABUSShould you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include Genfit (GNFT), Relay Therapeutics (RLAY), Erasca (ERAS), CARGO Therapeutics (CRGX), Anavex Life Sciences (AVXL), Cullinan Therapeutics (CGEM), Tectonic Therapeutic (TECX), Entrada Therapeutics (TRDA), ORIC Pharmaceuticals (ORIC), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry. Enanta Pharmaceuticals vs. Genfit Relay Therapeutics Erasca CARGO Therapeutics Anavex Life Sciences Cullinan Therapeutics Tectonic Therapeutic Entrada Therapeutics ORIC Pharmaceuticals Arbutus Biopharma Enanta Pharmaceuticals (NASDAQ:ENTA) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations. Does the media prefer ENTA or GNFT? In the previous week, Genfit had 2 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 4 mentions for Genfit and 2 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.00 equaled Genfit'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genfit 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ENTA or GNFT more profitable? Genfit has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -160.27%. Genfit's return on equity of 0.00% beat Enanta Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Enanta Pharmaceuticals-160.27% -63.75% -27.09% Genfit N/A N/A N/A Do analysts rate ENTA or GNFT? Enanta Pharmaceuticals currently has a consensus price target of $19.67, indicating a potential upside of 110.56%. Genfit has a consensus price target of $13.00, indicating a potential upside of 203.03%. Given Genfit's stronger consensus rating and higher probable upside, analysts plainly believe Genfit is more favorable than Enanta Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75Genfit 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in ENTA or GNFT? 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.2% of Genfit shares are owned by institutional investors. 13.6% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 4.2% of Genfit shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, ENTA or GNFT? Enanta Pharmaceuticals has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Genfit has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Which has better valuation & earnings, ENTA or GNFT? Genfit has higher revenue and earnings than Enanta Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnanta Pharmaceuticals$71.96M2.75-$133.82M-$5.45-1.71Genfit$76.06M2.82-$31.27MN/AN/A Does the MarketBeat Community favor ENTA or GNFT? Enanta Pharmaceuticals received 247 more outperform votes than Genfit when rated by MarketBeat users. However, 69.39% of users gave Genfit an outperform vote while only 56.76% of users gave Enanta Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEnanta PharmaceuticalsOutperform Votes31556.76% Underperform Votes24043.24% GenfitOutperform Votes6869.39% Underperform Votes3030.61% SummaryGenfit beats Enanta Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Ad Genesis Gold GroupBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTA vs. The Competition Export to ExcelMetricEnanta PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$197.91M$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-1.7110.35102.4617.58Price / Sales2.75362.011,234.85158.43Price / CashN/A52.6040.4736.33Price / Book0.9110.377.096.50Net Income-$133.82M$153.60M$119.65M$226.22M7 Day Performance-1.99%3.92%2.06%3.76%1 Month Performance-26.75%-6.78%-2.46%4.63%1 Year Performance3.89%33.23%33.95%29.20% Enanta Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTAEnanta Pharmaceuticals3.7197 of 5 stars$9.34+0.3%$19.67+110.6%+3.9%$197.91M$71.96M-1.71145News CoverageHigh Trading VolumeGNFTGenfit1.4465 of 5 stars$4.20-0.9%$13.00+209.5%+32.8%$209.79M$41.31M0.00120News CoverageRLAYRelay Therapeutics3.3008 of 5 stars$4.70+1.3%$21.22+351.5%-41.1%$786.69M$25.55M-1.78304ERASErasca2.7885 of 5 stars$2.77+6.5%$6.08+119.6%+20.5%$783.16MN/A-3.14126CRGXCARGO Therapeutics1.5402 of 5 stars$16.22+3.1%$30.33+87.0%+9.1%$746.61MN/A-3.69116AVXLAnavex Life Sciences3.7586 of 5 stars$8.80-2.4%$40.00+354.5%+36.0%$746.21MN/A-17.7240Upcoming EarningsCGEMCullinan Therapeutics2.0587 of 5 stars$12.70+3.9%$31.67+149.3%+47.9%$739.52M$18.94M-4.3030Analyst RevisionTECXTectonic Therapeutic3.4866 of 5 stars$47.62+6.1%$72.25+51.7%N/A$702.40MN/A-7.62120Analyst ForecastTRDAEntrada Therapeutics2.5382 of 5 stars$18.67+3.4%$24.00+28.5%+65.5%$698.63M$129.01M11.35110Positive NewsORICORIC Pharmaceuticals4.2201 of 5 stars$9.53+4.5%$18.29+91.9%+31.4%$672.53MN/A-5.0780Gap UpABUSArbutus Biopharma2.6471 of 5 stars$3.51+1.4%$5.50+56.7%+90.8%$665.12M$6.74M-8.1273Analyst Forecast Related Companies and Tools Related Companies GNFT Competitors RLAY Competitors ERAS Competitors CRGX Competitors AVXL Competitors CGEM Competitors TECX Competitors TRDA Competitors ORIC Competitors ABUS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ENTA) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
